BlackRock Inc. Invests $54.59 Million in Viemed Healthcare, Inc. $VMD

Key Points

• BlackRock acquired 4.79 million shares of Viemed Healthcare during the second quarter, valued at approximately $54.6 million and representing a 12.57% stake. Institutional investors collectively own 74.24% of the company.
• Viemed reported quarterly revenue of $78.1 million, roughly in line with estimates, but earnings of $0.07 per share missed consensus by $0.05. Analysts project full-year EPS of $0.41.
• The stock opened at $8.84, while analysts’ consensus target price is $14.00; ratings are mixed, with one Buy and three Holds. Two insiders also sold a combined 30,000 shares in late June.

BlackRock Inc. purchased a new stake in shares of Viemed Healthcare, Inc. (NASDAQ:VMD - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 4,788,307 shares of the company's stock, valued at approximately $54,587,000. BlackRock Inc. owned approximately 12.57% of Viemed Healthcare at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Kemnay Advisory Services Inc. acquired a new position in Viemed Healthcare during the fourth quarter worth $46,000. Quarry LP bought a new stake in shares of Viemed Healthcare during the 3rd quarter worth about $48,000. AQR Capital Management LLC bought a new stake in shares of Viemed Healthcare during the 1st quarter worth about $90,000. Diversified Trust Co acquired a new position in shares of Viemed Healthcare during the 1st quarter valued at about $107,000. Finally, Invesco Ltd. increased its holdings in shares of Viemed Healthcare by 25.5% during the 2nd quarter. Invesco Ltd. now owns 18,652 shares of the company's stock valued at $129,000 after acquiring an additional 3,795 shares during the last quarter. 74.24% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Timothy Smokoff sold 20,000 shares of the company's stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $11.50, for a total value of $230,000.00. Following the sale, the director owned 75,518 shares of the company's stock, valued at $868,457. The trade was a 20.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider William Frazier sold 10,000 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $11.72, for a total transaction of $117,200.00. Following the completion of the transaction, the insider directly owned 73,214 shares of the company's stock, valued at $858,068.08. This trade represents a 12.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 20.60% of the stock is currently owned by insiders.

Viemed Healthcare Trading Up 0.2%

Viemed Healthcare stock opened at $8.84 on Tuesday. The business has a 50 day moving average price of $10.79 and a two-hundred day moving average price of $9.90. The company has a quick ratio of 1.02, a current ratio of 1.13 and a debt-to-equity ratio of 0.04. The stock has a market cap of $336.72 million, a price-to-earnings ratio of 24.56, a price-to-earnings-growth ratio of 2.18 and a beta of 1.10. Viemed Healthcare, Inc. has a 12 month low of $6.05 and a 12 month high of $12.61.

Viemed Healthcare (NASDAQ:VMD - Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.05). Viemed Healthcare had a return on equity of 10.16% and a net margin of 4.81%.The firm had revenue of $78.10 million for the quarter, compared to analyst estimates of $78.00 million. As a group, equities analysts forecast that Viemed Healthcare, Inc. will post 0.41 EPS for the current year.

Wall Street Analysts Forecast Growth

VMD has been the subject of several analyst reports. Barrington Research started coverage on Viemed Healthcare in a report on Monday, August 24th. They issued an "outperform" rating and a $14.00 target price for the company. Wall Street Zen lowered shares of Viemed Healthcare from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 15th. Weiss Ratings cut shares of Viemed Healthcare from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Monday, August 17th. Finally, Freedom Capital lowered shares of Viemed Healthcare from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $14.00.

About Viemed Healthcare

Viemed Healthcare, Inc NASDAQ: VMD is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.

Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source